Stockscreener 앱 받기
18.69
5.30%
0.94
Moonlake Immunotherapeutics 주식(MLTX)의 최신 뉴스
Why did MLTX stock rise after-hours today? - MSN
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
How Sonelokimab’s FDA Pre-BLA Milestone And EULAR Data At MoonLake Immunotherapeutics (MLTX) Has Changed Its Investment Story - simplywall.st
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
InvestingPro Fair Value catches MoonLake before 63% biotech surge By Investing.com - Investing.com India
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MoonLake (NASDAQ: MLTX) shareholders approve equity plan expansion and re-elect director - Stock Titan
MLTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
Why Did MLTX Stock Rise After-Hours Today? - Stocktwits
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on axSpA data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention - simplywall.st
Trading Systems Reacting to (MLTX) Volatility - Stock Traders Daily
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? - AOL.com
MoonLake earnings in focus: BLA path for sonelokimab takes center stage - Investing.com
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress - Insider Monkey
MoonLake Secures Long-Term Manufacturing Capacity with Vetter Pharma - The Globe and Mail
MoonLake Immunotherapeutics Signs Manufacturing Agreement with Vetter Pharma – SEC 8-K Filing Details 8 - Minichart
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter - Investing.com UK
MoonLake Immunotherapeutics enters supply and capacity agreements with Vetter By Investing.com - Investing.com South Africa
MoonLake (NASDAQ: MLTX) secures Vetter supply and capacity agreements - Stock Titan
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
HC Wainwright & Co. Maintains MoonLake Immunotherapeutics (MLTX) Buy Recommendation - MSN
How Moonlake Immunotherapeutics (MLTX) Affects Rotational Strategy Timing - Stock Traders Daily
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filing - MSN
1.04%
0.76%
자본화:
|
볼륨(24시간):